Preview

Neurology, Neuropsychiatry, Psychosomatics

Advanced search

Pharmacoeconomic analysis of the use of first- and second-line drugs in the treatment of multiple sclerosis

https://doi.org/10.14412/2074-2711-2015-3-35-39

Full Text:

Abstract

Objective: to make a pharmacoeconomic comparison of the administration of first- and second-line drugs in the treatment of multiple sclerosis through cost, cost-effectiveness, and budget impact analyses using the 2015 state prices.

Material and methods. A pharmacoeconomic analysis was carried out on the basis of the data available in the literature on trials of the effects of the drugs on the rates of exacerbations and disability. On calculating, the authors took into account the current standards for the out- and inpatient management of patients with this nosological entity in accordance with the compulsory health insurance (CHI) program; prices for state drug purchases in March 2015; prices for medical services in compliance with the CHI standards in Moscow in 2015; the average sizes of minimum wage, salary, and disability grants with consideration for a discount rate of 3%. The cost-effectiveness and budget impact analyses were performed for intramuscular interferon (INF)-β1a (avonex, 30 μg), subcutaneous INF-β1a (rebif, 44 μg), subcutaneous INF-β1b (ronbetal, 8,000,000 IU), subcutaneous INF-β1b (betaferon, 9,600,000 IU), subcutaneous glatiramer acetate (copaxone, 20 mg), intravenous natalizumab (tyzabri, 300 mg), and oral fingolimod (gilenya, 0.5 mg).

Results and discussion. The second-line drug tyzabri outperforms the first-line agents for cost-effectiveness. The first-line drugs betaferon and copaxone is slightly exceeded in this indicator by tyzabri; the other both first- and second-line agents compared are all the more inferior in this indicator. The budget impact analysis has shown that the cost of the second-line drugs was higher than that of the first-line ones.

About the Authors

V. R. Mkrtchyan
Research and Practical Psychoneurology Center, Moscow Healthcare Department; Russian Medical Academy of Postgraduate Education, Ministry of Health of Russia
Russian Federation

43, Donskaya St., Moscow 115419;

2/1, Barrikadnaya St., Moscow 123995



L. V. Brylev
V.M. Buyanov City Clinical Hospital, Moscow Healthcare Department
Russian Federation
26, Bakinskaya St., Moscow 115516


O. V. Davydova
Research and Practical Psychoneurology Center, Moscow Healthcare Department
Russian Federation
43, Donskaya St., Moscow 115419


A. V. Belyanin
International Institute of Economics and Finance, National Research University Higher School of Economics
Russian Federation
26, Shabalovka St., Build. 3, Moscow 119049


I. A. Shpak
Research and Practical Psychoneurology Center, Moscow Healthcare Department
Russian Federation
43, Donskaya St., Moscow 115419


A. M. Sergeev
Institute of Applied Economic Researches, Russian Presidential Academy of National Economy and Public Administration
Russian Federation
84, Vernadsky Prospect, Moscow 119606


References

1. Лиждвой ВЮ, Сергеев СА, Гуров АН, Туровский БМ. Эпидемиология рассеянного склероза в Московской области. Альманах клинической медицины. 2006;(13):68. [Lizhdvoi VYu, Sergeev SA, Gurov AN, Turovskii BM. Epidemiology of multiple sclerosis in the Moscow region. Almanac of Clinical Medicine. 2006;(13):68. (In Russ.)].

2. Гусев ЕИ, Завалишина ИА, Бойко АН, редакторы. Рассеянный склероз. Москва: Реал Тайм; 2011. 528 c. [Gusev EI, Zavalishina IA, Boiko AN, editors. Rasseyannyi skleroz [Multiple sclerosis]. Moscow: Real Time; 2011. 528 p.].

3. Шмидт ТН, Яхно НН. Рассеянный склероз. Руководство для врачей. Москва: МЕД-пресс-информ; 2010. 272 с. [Shmidt TN, Yakhno NN. Rasseyannyi skleroz. Rukovodstvo dlya vrachei [Multiple sclerosis. A guide for physicians]. Moscow: MEDpress-inform; 2012. 272 p.].

4. Гусев ЕИ, Бойко АН. Рассеянный склероз: достижения десятилетия. Журнал неврологии и психиатрии им. С.С. Корсакова. 2007;(4):4-13. [Gusev EI, Boiko AN. Multiple sclerosis: Achievements decade. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2007;4(Multiple sclerosis):4–13. (In Russ.)].

5. Сабанов АВ, Лунева АВ, Матвеев НВ. Фармакоэкономический анализ эффективности применения натализумаба при рецидивирующе-ремиттирующем рассеянном склерозе. Журнал неврологии и психиатрии им. С.С. Корсакова. 2014;(5):65–9. [Sabanov AV, Luneva AV, Matveev NV. Pharmacoeconomic analysis of the efficacy of natalizumab in relapsing-remitting multiple sclerosis. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2014;(5):65-9. (In Russ.)].

6. Tramacere I, Del Giovane C, Salanti G, et al. Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis (Review). Copyright© 2015 The Cochrane Collaboration. JohnWiley & Sons, Ltd. 127 р.

7. Filippini G, Del Giovane C, Vacchi L, et al. Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis (Review). Copyright© 2013 The Cochrane Collaboration. Published by JohnWiley & Sons, Ltd. 137 р.

8. Инструкция по применению лекарственного препарата для медицинского применения Ронбетал© (интерферон β1b, раствор для подкожного введения). Государственный реестр лекарственных средств. [Instruktsiya po primeneniyu lekarstvennogo preparata dlya meditsinskogo primeneniya Ronbetal® (interferon β1b, rastvor dlya podkozhnogo vvedeniya). Gosudarstvennyi reestr lekarstvennykh sredstv]. http://grls.rosminzdrav.ru


For citation:


Mkrtchyan V.R., Brylev L.V., Davydova O.V., Belyanin A.V., Shpak I.A., Sergeev A.M. Pharmacoeconomic analysis of the use of first- and second-line drugs in the treatment of multiple sclerosis. Neurology, Neuropsychiatry, Psychosomatics. 2015;7(3):35-39. (In Russ.) https://doi.org/10.14412/2074-2711-2015-3-35-39

Views: 460


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2074-2711 (Print)
ISSN 2310-1342 (Online)